These are the companies in the private sector that medtech analysts have called attention to in 2021.

Johnson & Johnson's third-quarter earnings suggest that orthopedic surgeons are prioritizing hips over knees as they work through their COVID-related backlog.

Medtronic continues to boost its spine portfolio by incorporating Titan nanoLOCK surface technology inherited from its 2019 acquisition of Titan Spine.

By divesting its extremity orthopedics business to Smith & Nephew, Integra LifeSciences should be able to focus on areas with a higher potential for growth.

With the death of Supreme Court Justice Ruth Bader Ginsburg, legal scholars see an increased chance that the Affordable Care Act is overturned. What will this mean for medtech?

Precision OS Technology released details of what the company says is a "major breakthrough" in portable arthroscopy training.

A newly published study examines surgical proficiency in orthopedic procedures with and without VR training. The results may surprise you.

Will Conformis inadvertently diminish the value of its customized knee implants it's known for by adding a "standard" knee to its portfolio?

Zimmer Biomet revenue across all categories exceeded analyst expectations in the second quarter, despite COVID-19 disruptions, and Rosa placements were also surprisingly strong.